Abstract: Substituted phenylpyrrolecarboxamide compounds such as those represented by Formula A can be used in the treatment of HIV infection and related conditions.

Abstract: A system, method, and apparatus for transferring blood donation files are disclosed. An example system includes a collection device located at a blood donation site and a collection server located in a remote location. The example collection device is configured to store blood donation information from blood donors within a blood donation batch file located at a designated directory of a memory, and store metadata related to the blood donation information to the blood donation batch file. The example collection device also transmits the blood donation batch file to a registered user device. The example collection server is configured to determine the registered user device is available via a network connection. Responsive to determining the user device is connected, the collection server acquires the blood donation batch file from the user device and aggregates the blood donation batch file with blood donation batch files received from other registered user devices.

Abstract: The present disclosure provides virus like nanoparticles (VLPs), which are capable of displaying multiple copies of a SARS-CoV-2 antigen, for eliciting protective immunity against a SARS-CoV-2 infection, as well as polypeptides, compositions and methods thereof.

Abstract: Provided herein are engineered red blood cells expressing rare blood antigen group profiles, and methods of making use the same, are described. Also provided are recombinant reagent red blood cells that express or lack the expression of at least one protein (e.g., a blood group antigen) on its surface and uses thereof.

Abstract: Described herein are immunogenic compositions for preventing infection with Middle East respiratory syndrome coronavirus (MERS-CoV) wherein the immunogenic compositions comprise at least a portion of the MERS-CoV S protein and an immunopotentiator.

Abstract: Substituted phenylpyrrolecarboxamide compounds such as those represented by Formula A can be used in the treatment of HIV infection and related conditions.

Abstract: A system, method, and apparatus for transferring blood donation files are disclosed. An example system includes a collection device located at a blood donation site and a collection server located in a remote location. The example collection device is configured to store blood donation information from blood donors within a blood donation batch file located at a designated directory of a memory, and store metadata related to the blood donation information to the blood donation batch file. The example collection device also transmits the blood donation batch file to a registered user device. The example collection server is configured to determine the registered user device is available via a network connection. Responsive to determining the user device is connected, the collection server acquires the blood donation batch file from the user device and aggregates the blood donation batch file with blood donation batch files received from other registered user devices.

Abstract: Substituted phenylpyrrolecarboxamide compounds such as those represented by Formula A can be used in the treatment of HIV infection and related conditions.

Abstract: The disclosure provides methods of making a cell-containing product having a uniform amount of cells therein. The method comprises pooling red blood cells from a plurality of blood units, and inactivating any pathogen contained therein. A storage solution added to the cellular component results in a cell-containing product that is essentially pathogen and white blood cell free and has an extended shelf life of about 42 to about 100 days. The cell-containing product is further divided into units which comprise a uniform dose of RBCs per unit.

Abstract: Substituted phenylpyrrolecarboxamide compounds such as those represented by Formula A can be used in the treatment of HIV infection and related conditions.

Abstract: Substituted phenylpyrrolecarboxamide compounds such as those represented by Formula A can be used in the treatment of HIV infection and related conditions.

Abstract: The disclosure provides methods of making a red blood cell, plasma, and platelet products having a uniform dose and volume. The method comprises pooling a plurality of blood units, leukoreducing the blood and inactivating any pathogen contained therein. Plasma, RBCs, and platelets are then divided into uniform dose and volume units which have an extended shelf life.

Abstract: Substituted phenylpyrrolecarboxamide compounds such as those represented by Formula A can be used in the treatment of HIV infection and related conditions.

Abstract: The disclosure provides methods of making a cell-containing product having a uniform amount of cells therein. The method comprises pooling red blood cells from a plurality of blood units, and inactivating any pathogen contained therein. A storage solution added to the cellular component results in a cell-containing product that is essentially pathogen and white blood cell free and has an extended shelf life of about 42 to about 100 days. The cell-containing product is further divided into units which comprise a uniform dose of RBCs per unit.

Abstract: Disclosed herein are immunogenic compositions for preventing infection with influenza viruses wherein the immunogenic compositions comprises an immunogen such as a hemagglutinin of an influenza virus, and an immunopotentiator such as an Fc fragment of human IgG and optionally a stabilization sequence. The immunogen is linked to the stabilization sequence which in turn is linked to the immunopotentiator.

Abstract: Described herein are immunogenic compositions for preventing infection with Middle East respiratory syndrome coronavirus (MERS-CoV) wherein the immunogenic compositions comprise at least a portion of the MERS-CoV S protein and an immunopotentiator.

Abstract: Methods for obtaining purified populations of megakaryocytes and platelets by ex vivo culture of stem cells are provided herein.

Abstract: Disclosed herein are trimeric polypeptide pharmaceutical compositions comprising three monomers, each monomer comprising a polypeptide having the amino acid sequence of the N-terminal heptad repeat (NHR or HR1) or C-terminal heptad repeat (CHR or HR2) of the transmembrane glycoprotein of human immunodeficiency virus (HIV) and a trimerization motif.

Abstract: Disclosed herein are neutralizing antibodies with cross-neutralizing activity and cross-protective effects against divergent stains of influenza virus, which are specific for an epitope having at least 90% homology to amino acids +72-115 of the HA1 domain of H5N1 influenza virus hemagglutinin.

Abstract: Disclosed herein are immunogenic compositions for preventing infection with influenza viruses wherein the immunogenic compositions comprises an immunogen such as a hemagglutinin of an influenza virus, and an immunopotentiator such as an Fc fragment of human IgG and optionally a stabilization sequence. The immunogen is linked to the stabilization sequence which in turn is linked to the immunopotentiator.